Our client wished to identify value-creation "hot spots" in European perinatal care ecosystems. With these hotspots identified, they then wished to identify and assess technology, drug and device assets that had the greatest potential to address them. With these identified and profiled, we supported our client to perform deeper dive assessments into target assets based on demand, impact, ecosystem and commercial value.


Using Umio Health Value Design®, we:

  • Mapped the perinatal service ecosystem and how it varied in the EU5 (UK, France, Germany, Italy and Spain)

  • Performed a deep analysis of perinatal complications, incidence, cost and trend data

  • Modelled individual perinatal disease-conditions against a pre-term, term and post-natal timeline to answer the questions: Where to intervene? What opportunities? What strategy? What assets?

  • Identified core unmet needs, contexts, resources and emergent factors

  • Designed and framed ten high-leverage value propositions

  • Searched for, profiled and scored 52 attractive perinatal ecosystem assets spanning drug, device and technology classes and allocated them to the different value propositions

  • Supported our client to assess high-scoring assets on commercial, strategic, access and ecosystem value criteria


Most current perinatal research and development / innovation activity is focused on treatments and not on prevention, in part due to the lack of understanding of the multiple aetiology of different perinatal conditions. Innovation in the perinatal area is focused on four main streams of activity:

  • Preventing pre-term births through research into its causes. A major scientific knowledge gap exists and a large co-ordinated global effort is underway to discover the biological mechanisms leading to pre-term births. Much of this effort is driven by a pressing need to reduce pre-term births in middle- and low-income countries led by the “Born too Soon” 2012 WHO and UN initiative.

  • Improving screening and diagnostics of at-risk mothers, fetus and births to ensure that a mother and child receive the best care in the most effective setting

  • Delaying pre-term births to advance fetal maturity, especially of the lungs, to prevent neonatal and childhood complications and impairment. Pre-term post-natal complications contribute greatest to the consequent cost of payers

  • Improving pre-term neonatal care through advances in drugs and their administration, and intensive care unit monitoring and diagnostic technologies

Our client is in active discussions with asset owners, and we continue to support their efforts to evaluate the value potential of new innovations in the perinatal care ecosystem.